Rhythm Biosciences Limited (ASX:RHY)

Australia flag Australia · Delayed Price · Currency is AUD
0.140
-0.010 (-6.67%)
Apr 29, 2026, 4:10 PM AEST
112.12%
Market Cap 53.08M
Revenue (ttm) 1.65M
Net Income (ttm) -6.68M
Shares Out 353.87M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 933,963
Average Volume 613,348
Open 0.145
Previous Close 0.150
Day's Range 0.137 - 0.145
52-Week Range 0.047 - 0.280
Beta 0.60
RSI 31.91
Earnings Date May 19, 2026

About Rhythm Biosciences

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Australia. [Read more]

Sector Healthcare
Founded 2017
Country Australia
Stock Exchange Australian Securities Exchange
Ticker Symbol RHY
Full Company Profile

Financial Performance

In fiscal year 2025, Rhythm Biosciences's revenue was 3.19 million, an increase of 88.85% compared to the previous year's 1.69 million. Losses were -3.83 million, -44.15% less than in 2024.

Financial Statements

News

There is no news available yet.